Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aesthetic Technologies Forum In Brief

This article was originally published in The Gray Sheet

Executive Summary

Isolagen wrinkle treatment: Isolagen estimates FDA approval for its autologous cellular "self-therapy" by summer 2005, Vaughan Cliff, VP and medical director, told attendees at the Feb. 9 Aesthetic Technologies Forum in Washington, D.C. Starting with a 3 mm x 7.5 mm patch of biopsied skin from behind the ear, the treatment cultures fibroblasts, which are reinserted into the patient's dermis, regenerating collagen and tissue. Burn and acne applications also are under consideration. The ten-site, double-blind, 152-patient, Phase III wrinkle trial began in August under an investigational new drug application and will include four-month follow-up. Data analysis is due in March, with a marketing submission expected in November or December...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel